With Gilead’s (NASDAQ: GILD) recent announcement about the 7977 data(100% RVR, 25/25 in genotype 1 patients so far) should have Idenix(NASDAQ: IDIX) and Achillion(NASDAQ: ACHN) investors thinking hard about the.
Below are some brief note on about a dozen stocks that we felt compelled to brief subscribers on. Today, the briefing documents and panel attendees list for Amgen’s (NASDAQ: AMGN).
We wanted to throw out some trading ideas for some stocks that we are following, but may not necessarily get full write-ups on in time. Ideally, we will have research.
Analyst Notes: These kind of things are troubling because of the cardiovascular nature of the FDA’s qualms. However, give it a 50% success probability “In the second CRL, Amylin and.
Both Achillion and Ariad hit 52-week highs today after running up on positive news. While we continue to believe the companies will be successful, we also believe the stocks are.
Onyx Pharmaceuticals(ONXX) submitted their NDA for Carfilzomib to the FDA under the accelerated approval process on 9/28/11 and are seeking a 6-month priority review. At the earliest, they could be.
We fully expected that pSivida(NASDAQ: PSDV) and Alimera Sciences(NASDAQ:ALIM) will receive another Complete Response Letter for ILUVIEN in the treatment of diabetic macular edema (DME). We see little reason for.
Video: http://content.screencast.com/users/biotechtraderHB/folders/Default/media/e7f5888c-ae53-412d-ad9e-36eee29a425b/$INHX110911.swf Analyst Notes: INHX showed only 7 day viral reduction data, which has not been shown to be highly correlated to a sustained viral response. What we want to.
Incyte Pharmaceuticals is awaiting FDA approval of its lead compound Ruxolitinib (INCB18424) for the treatment of Myelofibrosis (MF) with an expected decision date on December 3, 2011. Our analysis suggests.
Its end of year 2011 and there are a large quantity of trading opportunities approaching. On the docket: $ALIM – PDUFA (NOV 12, 2011) $SPPI – PDUFA (NOV 20, 2011).
HIGHLY SPECULATIVE TRADE Overview In May 2011 BioMimetic Therapeutics (BMTI) received a positive recommendation from the FDA Advisory Committee for their Augment Bone Graft technology. Despite this, the FDA was.
Overview In the next several weeks Depomed (DEPO) is expected to announce top-line results from it’s large Phase 3 clinical trial for Serada, an investigational non-hormonal treatment for post-menopausal hot.